GlobalData on MSN4d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
Gilead’s HIV Shot Reduced Infections By 96% In Late-Stage Trial—Beating Daily Pill
Gilead Science’s twice-yearly shot for treating HIV prevented new infections by 96% among patients in a late-stage trial, ...
GlobalData on MSN8d
Gilead’s twice-yearly lenacapavir outperforms Truvada in men
If approved, lenacapavir would be the first and only twice-yearly HIV prevention choice for people who need or want PrEP.
BioSpace7d
Gilead Touts 96% HIV Risk Reduction With Twice-Yearly PrEP, Eyes Regulatory Filings
Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...
US-based pharma giant Gilead Sciences wants HIV drug Lenacapavir patented
On September 19, 2024, the Indian Patent Office will hear objections filed by Sankalp Rehabilitation Trust against Gilead's ...
Patent opposition case against Gilead’s long-acting HIV injectable drug, comes up this week
The US-based Gilead Sciences’ long-acting injectable HIV drug lenacapavir is at the centre of a patent opposition case ...
AOL7d
Gilead’s biannual HIV shot reduced risk of infections by 96 percent, company says
Drugmaker Gilead Science announced Thursday that its biannual injections to prevent against HIV had slashed the risk of ...
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...
Buy Rating on Gilead Sciences: Underestimated Market Potential of Lenacapavir in HIV Treatment and Prevention
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...
Hold Rating on Gilead Sciences Amid Lenacapavir’s Promise and Market Uncertainties
Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...
Yahoo Finance5d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said. Early lenacapavir ...